Brief: Aptevo Therapeutics Announces New Preliminary Remission Data On Four Additional Patients Enrolled In On-Going Apvo436 Dose Expansion Phase 1B Trial

Aptevo Therapeutics

09/06/2022 13:19

June 9 (Reuters) - Aptevo Therapeutics Inc  APVO.O :
    * APTEVO THERAPEUTICS ANNOUNCES NEW PRELIMINARY REMISSION
DATA ON
FOUR ADDITIONAL PATIENTS ENROLLED IN ON-GOING APVO436 DOSE
EXPANSION PHASE 1B TRIAL FOR THE TREATMENT OF ACUTE MYELOID
LEUKEMIA
    * APTEVO THERAPEUTICS INC- COHORT 1 COMBINATION THERAPY ARM
SHOWS
36% REMISSION RATE AMONG RESPONSE-EVALUABLE PATIENTS TREATED TO
DATE
    * APTEVO THERAPEUTICS INC- COHORT 3 MONOTHERAPY PATIENT
ACHIEVED
BONE MARROW COMPLETE REMISSION
    * APTEVO THERAPEUTICS INC- MYELODYSPLASTIC SYNDROME PATIENT
ENROLLED IN DOSE ESCALATION TRIAL REMAINS STABLE AND ON APVO436
AFTER 18 MONTHS OF TREATMENT

Source text for Eikon:  ID: 
Further company coverage:  APVO.O 

 ((reuters.briefs@thomsonreuters.com;))